Summary & Overview
HCPCS G9098: Esophageal Cancer Disease Status Assessment
HCPCS Level II code G9098 designates an oncology disease-status assessment specific to esophageal cancer when adenocarcinoma or squamous cell carcinoma is the predominant histology and the disease is metastatic, locally recurrent, progressive, or m1 at diagnosis. The code is documented for use in Medicare-approved demonstration projects and is relevant to clinicians, billing staff, and policy analysts tracking cancer-focused demonstration initiatives. Nationally, the code matters because it standardizes reporting for advanced esophageal cancer cases within demonstration contexts and can affect data capture for outcomes and program evaluation.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for the code, expected sites of service, and which payer relationships are typically involved. The publication provides benchmarks where available, summaries of relevant policy or coverage considerations, and practical billing context for inclusion in demonstration project workflows. Data not available in the input will be noted explicitly where applicable. This overview is intended for a national audience of oncology program managers, revenue cycle leaders, and policy stakeholders seeking clarity on the purpose and typical use settings for G9098.
Billing Code Overview
HCPCS Level II code G9098 describes oncology disease status assessment for esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as the predominant cell type. The code applies when the disease is m1 at diagnosis, metastatic, locally recurrent, or progressive, and is identified for use within a Medicare-approved demonstration project.
Service Type: Oncology — disease status assessment
Typical Site of Service: Hospital outpatient departments, cancer centers, and specialty oncology clinics
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 67-year-old man with known esophageal adenocarcinoma presents to a multidisciplinary oncology clinic after imaging and endoscopic biopsy show distant metastatic disease at diagnosis (M1). He has progressive dysphagia, weight loss, and new liver lesions on CT consistent with metastatic spread. The patient is enrolled in a Medicare-approved demonstration project tracking disease status and outcomes for advanced esophageal cancer. The clinical workflow includes review of staging scans, pathology confirmation of predominant adenocarcinoma cell type, documentation of metastatic (M1), locally recurrent, or progressive disease status, multidisciplinary tumor board discussion, and longitudinal outcome reporting to the demonstration project. Billing uses the HCPCS Level II code G9098 to indicate disease status documentation specific to esophageal cancer (adenocarcinoma or squamous cell carcinoma predominant) when criteria for the demonstration project are met. Typical clinicians involved include medical oncologists, radiation oncologists, surgical oncologists, gastroenterologists, and certified tumor registrars. Typical site of service is an outpatient oncology clinic or hospital outpatient department with coordination for imaging and pathology services. Typical patient scenario: an outpatient follow-up visit after diagnostic staging, where the clinician documents metastatic or progressive disease status and submits G9098 for the demonstration project reporting requirement.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|